Healthcare Marketing Compliance: What Practices Can and Can’t Say

Every ad a medical practice runs, every email it sends, every text reminder and every reply to an online review sits inside a set of rules that most other local businesses never have to think about. A restaurant can post a customer’s photo, run a retargeting pixel and offer a discount for a five-star review without a second thought. A practice cannot do any of those things casually, because each one touches a regulated area. Healthcare marketing compliance is the discipline of running patient acquisition inside those rules, and it rests on four rule-setters that overlap on almost every campaign: the HIPAA Privacy Rule and the agency that enforces it, the Federal Trade Commission, the state medical board that licenses the providers, and the advertising platforms themselves. Each one restricts something different, and the mistakes that get practices in trouble are rarely deliberate. They come from using general-market tools and tactics, including everyday healthcare social media marketing, in an environment they were never designed for. This article is general information for practice owners and managers, not legal advice; questions about a specific campaign or situation belong with the practice’s healthcare counsel.

The reassuring part is that compliant marketing and effective marketing are not opposites. Most of what fills a schedule, including service pages, search ads, educational content and a steady review profile, works perfectly well inside the rules once a practice understands where the lines sit. The rest of this article walks through each rule-setter in turn, then shows how to build compliance into the marketing workflow so it stops being a source of anxiety and becomes a routine.

Start with HIPAA, because it reaches further into a marketing stack than most practice owners expect. Protected health information is any data that identifies a person and connects to their health, the care they received or payment for that care. The definition sounds simple until it meets a real website. A visitor who opens a page about a specific treatment while a third-party script records their device and network details has, in combination, produced something that can qualify as protected health information, even though no form was submitted and no appointment was booked. That is the distinction that separates healthcare marketing from every other kind: the data a campaign generates is not neutral, and how it is collected, stored and shared determines whether the practice is operating within the rules or sitting on a reportable problem.

The most common exposure is not ad copy. It is the invisible code running behind the website. Standard analytics tags, advertising pixels and retargeting scripts send information about visitor behavior to outside platforms as it happens. When that behavior involves a health-related page, the platform receives a signal about health intent attached to an identifiable device, and most advertising platforms will not sign the business associate agreement that would make that handoff permissible. The federal government has addressed this directly: the HHS Office for Civil Rights has published guidance on online tracking technologies that practices should read before adding any pixel, analytics script or chat widget to a page where patients might be present. Pages for behavioral health, fertility, weight management and similar services carry the highest risk, because the health context is strongest.

The same logic governs contact forms, scheduling widgets, chat tools and the vendors behind them. Any tool that captures a name alongside a health inquiry is handling protected information, and the vendor needs a business associate agreement in place. Many consumer-grade marketing platforms will not sign one, which is a useful filter when choosing tools. HIPAA also reaches into review management. Even when a patient discloses their own diagnosis in a public review, a practice confirming or denying that the person was ever a patient has disclosed protected information. The compliant reply thanks the reviewer, acknowledges the feedback in general terms and offers a private contact, and it says nothing about the visit, the treatment or the clinician. Email and text programs sit under the same rule: a reminder about tomorrow’s appointment is a healthcare operation, but the moment a promotional offer is added to that message, it becomes marketing and the authorization rules change. Keeping transactional and marketing lists separate is the simplest way to avoid applying the wrong rules to the wrong message.

The Federal Trade Commission regulates something different. Where HIPAA protects patient information, the FTC protects the public from advertising that is false, unsupported or misleading, and it applies the same standard whether the advertiser is a supplement company or a dermatology practice. Health-related claims draw the closest scrutiny. A practice that says a treatment produces a particular result needs to be able to support that statement, and the more specific the promise, the stronger the support has to be. This matters most in cash-pay and elective areas where the marketing tends to lean on outcomes, from aesthetics to weight management to hormone replacement therapy marketing, where the gap between what a patient hopes for and what the evidence supports can be wide. The safe habit is to describe what a treatment is for, who is typically a candidate and what the consultation covers, and to leave outcome language to the clinician in the exam room.

Testimonials, reviews and endorsements are the second half of the FTC’s interest. A testimonial has to reflect the honest experience of a real patient, and if that patient received anything of value for sharing it, the relationship has to be disclosed. The same applies to influencers, local personalities or anyone else a practice compensates to talk about it. Reviews are where practices most often stumble without meaning to. Offering a discount, a gift or a drawing entry in exchange for a review violates both the FTC’s expectations and the policies of every major review platform, and selectively asking only happy patients to post, a practice sometimes called gating, is treated the same way. The FTC’s own Endorsement Guides questions and answers explain the disclosure rules in plain language and are worth sharing with anyone who touches the practice’s reviews or social accounts. Before-and-after photos deserve a note here too: they are a form of outcome claim, they usually require written patient authorization under HIPAA, and cropping a face does not by itself make a photo anonymous if other features still identify the person.

The third rule-setter is the state medical board, and it is the one practice owners most often overlook because it is the least uniform. Federal rules are the same in every state. Board rules are not. Each state licenses its providers under its own practice act, and most of those acts include provisions on advertising that go beyond anything HIPAA or the FTC requires. Common areas include how a provider may describe credentials and specialties, whether the word “specialist” or “board-certified” can be used and under what conditions, how before-and-after imagery can be displayed, whether patient testimonials are permitted at all, and how pricing and promotions can be presented. Several states restrict testimonials for licensed providers outright, and several more impose specific disclosure requirements on aesthetic and cosmetic advertising that a general-market agency would never think to check.

The practical consequence is that a campaign built in one state cannot simply be copied to another, and a practice with locations across state lines may need different versions of the same page. The board also governs the people behind the marketing. A clinician’s name on an ad ties that ad to a license, which means the clinician, not the marketing vendor, is the one who answers for it if a complaint is filed. Every practice should know where its board publishes its advertising rules and should read them before launching anything new. When the rules are unclear, the practice’s counsel is the right place to ask, because a board complaint is a professional matter rather than a marketing one.

The fourth rule-setter is often the one that disrupts a practice fastest: the advertising platforms. Google and Meta each publish healthcare advertising policies that decide which treatments can be promoted, which require certification, which are restricted and which are prohibited. These policies are enforced by automated review before a human ever reads a complaint, and the consequence of a violation is immediate: the ad is disapproved, and repeated problems can suspend the account entirely. Regenerative and cell-based treatments are a well-known example, which is why a stem cell marketing agency has to build campaigns around the platform rules rather than around the treatment’s benefits. A practice that loses its ad account loses its fastest patient acquisition channel, and winning an appeal can take weeks.

Other categories sit in the restricted tier rather than the prohibited one. Treatments involving controlled substances, prescription medications or emerging therapies can often be advertised, but only with the right certifications, the right landing-page language and careful avoidance of outcome promises. Practices in those areas learn quickly that the landing page matters as much as the ad, because the platforms review the destination too. Thoughtful ketamine clinic marketing is a good illustration: the campaigns that stay live are the ones that describe the clinic, the consultation and the clinical oversight rather than the experience of the treatment itself. The platforms also apply their own rules to audience targeting. Uploading patient lists to build a custom audience, or targeting based on inferred health conditions, raises both platform-policy and HIPAA problems at once, and both platforms have narrowed what is permitted for health advertisers.

Referrals and incentives deserve their own short treatment, because they are where marketing habits from other industries most often collide with healthcare law. Rewarding a patient for leaving a review is a platform and FTC problem, as covered above. Rewarding a patient for bringing in a friend, or rewarding another provider for sending patients, raises a different set of questions that depend on who pays for the care and how the reward is structured. Federal fraud and abuse laws govern inducements involving patients and referral sources, and state laws add their own layers. None of this means a practice cannot build a patient referral program; it means the program has to be designed with counsel, with the reward structure and the payer mix in view, rather than borrowed from a software company’s playbook. The same caution applies to physician referral relationships, where even a modest gift can be read as an inducement.

With the four rule-setters understood, the question becomes how a busy practice keeps all of this straight without hiring a compliance department. The answer is to build the rules into the workflow so that nobody has to remember them in the moment. Start with a short set of pre-approved language for the situations that recur: review replies, service descriptions, credential statements and promotional offers. Add a review step before anything goes live, with one person accountable for checking it against the four rule-setters, and make that person’s sign-off part of the process rather than a favor. Keep a vendor inventory that lists every tool touching the website, the email list or patient contact data, and confirm which of them have signed business associate agreements. Audit the authorizations behind every testimonial and photo currently in use, because missing paperwork on live content is an active exposure rather than a theoretical one.

There is a quieter benefit to doing this well. The qualities that keep a practice compliant, including specific and accurate descriptions of services, named and credentialed authorship, consistent information across the website and directory listings, and restraint around outcome claims, are the same qualities that search engines and AI-generated answers reward when they decide which practices to cite. A practice that has done the compliance work has usually also done most of the work that improves its AI-driven search visibility, because both depend on being a reliable, consistent source of information about what the practice does and who does it.

Compliance also works best when it is part of how a practice acquires patients rather than a check applied afterward. That is the thinking behind A.L.I. 360 by Target Patients MD. A.L.I. 360 by Target Patients MD is a proprietary AI-powered patient-acquisition system for medical and dental practices. The name stands for Attract, Learn, and Influence. It is built for the regulatory environment practices operate in, so the campaigns it drives are designed from the start to keep patient information where it belongs.

Healthcare marketing compliance is not a reason to market less. It is the set of conditions under which marketing keeps working: ads that stay live, reviews that stand, a website that does not leak patient information, and a reputation that holds up when someone looks closely. Practices that build the rules into their routine stop treating compliance as a risk and start treating it as part of how they grow. If you would like a second look at how your practice’s marketing holds up against the four rule-setters, request a practice growth session.

Here are direct answers to the questions practices ask most often.

• What is healthcare marketing compliance?
  It is the practice of running patient acquisition within the rules set by HIPAA and HHS, the Federal Trade Commission, state medical boards and the advertising platforms. Each governs something different: patient information, truthful claims and endorsements, advertising by licensed providers, and what can be promoted on Google and Meta. A compliant program accounts for all four at once.
• Can a medical practice use analytics tools or advertising pixels on its website?
  It depends on what the tool collects and where the data goes. Scripts that send identifiable visitor data from health-related pages to third parties can create a protected-health-information disclosure, and most advertising platforms will not sign a business associate agreement. Practices should review the HHS guidance on online tracking technologies, limit what runs on sensitive pages and prefer configurations that strip identifiers before data leaves the practice’s environment.
• Are patient testimonials allowed in healthcare advertising?
  Often, but with conditions. The patient must give written authorization for their information to be used in marketing, the testimonial must reflect their honest experience, and any compensation must be disclosed under FTC rules. Some state medical boards restrict or prohibit testimonials for licensed providers, so the state rules have to be checked before any testimonial is published.
• Can a practice offer patients a reward for referrals or reviews?
  Rewarding reviews breaks the policies of every major review platform and conflicts with FTC disclosure expectations, so the answer there is no. Referral rewards involving patients or other providers raise questions under federal and state fraud and abuse laws that depend on how care is paid for and how the reward is structured, and a referral program should be designed with the practice’s counsel.
• Who is responsible for compliance when an agency runs the marketing?
  The practice. As the licensed provider and the covered entity, the practice carries the obligation regardless of who executed the campaign. A good agency builds compliant campaigns and signs a business associate agreement where it handles patient data, but the practice should still keep its own review step and its own records of authorizations and vendor agreements.